Rankings
▼
Calendar
CTNM FY 2024 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$504M
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
-100.0% YoY
Gross Profit
-$258,000
Operating Income
-$51M
Net Income
-$42M
EPS (Diluted)
$-2.18
Cash Flow
Operating Cash Flow
-$33M
Free Cash Flow
-$33M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$213M
Total Liabilities
$15M
Stockholders' Equity
$198M
Cash & Equivalents
$22M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$50M
-100.0%
Gross Profit
-$258,000
$50M
-100.5%
Operating Income
-$51M
-$16M
-216.6%
Net Income
-$42M
$23M
-286.0%
← Q4 2023
All Quarters
Q1 2024 →